Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial

导出原文传递

翻译打印收藏纠错

作者： Abe, Masatoshi ^[1] ; Nishigori, Chikako ^[2] ; Torii, Hideshi ^[3] ; Ihn, Hironobu ^[4] ; Ito, Kei ^[5] ; Nagaoka, Makoto ^[6] ; Isogawa, Naoki ^[7] ; Kawaguchi, Isao ^[8] ; Tomochika, Yukiko ; Kobayashi, Mihoko ; Tallman, Anna M. ; Papp, Kim A.

作者单位： Kumamoto Univ, Kumamoto, Japan ^[1] Probity Med Res, Waterloo, ON, Canada ^[2] Tokyo Yamate Med Ctr, Div Dermatol, Tokyo, Japan ^[3] Kobe Univ, Div Dermatol, Kobe, Hyogo, Japan ^[4] Pfizer Japan Inc, Tokyo, Japan ^[5] Sapporo Skin Clin, Sapporo, Hokkaido, Japan ^[6] JR Sapporo Hosp, Sapporo, Hokkaido, Japan ^[7] Pfizer Inc, New York, NY USA ^[8]

关键词 Janus kinase inhibitor Japanese oral medicine plaque psoriasis tofacitinib

发布时间 2018-03-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交